The Global Health Body Issues Concern Over Acute Lack of Obesity Jabs
Fewer than a tenth of people that would benefit from GLP-1 drugs like Wegovy can access them, caution the global health agency as it releases its first recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging broader and more equitable access to this class of drugs.
Per estimates, over two billion could be obese by 2030 if no action is taken.
"Our new guidelines affirms that excess weight is a long-term condition that can be addressed with thorough and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are key barriers to universal access to the jabs that can help people shift substantial weight, explains the organization.
GLP-1 Therapy Shortage
Even under the current best projected outlook, the supply of these medications could only cover approximately 100 million people – fewer than 10% of the global need, per the WHO.
The advice calls on nations and manufacturers to expand availability, by strategies including licensing agreements.
Exclusive production rights on the active ingredient – the primary component of a leading brand – is due to expire in several nations in 2026.
The Way Weight-Loss Jabs Function
GLP-1 drugs mimick a biological compound to delay gastric emptying, reduce hunger and increase the sense of being full so people eat less.
Patients typically see weight reduction in the initial weeks of starting on the weekly injections.
Research suggests people may see weight return a year later of discontinuing the medication, because their normal food cravings come back.
To be overweight or obese raises your chance for experiencing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity impacts people in all nations and was associated with millions of deaths worldwide in 2024, per the health agency.
